$222 Million is the total value of Opaleye Management Inc.'s 47 reported holdings in Q2 2022. The portfolio turnover from Q1 2022 to Q2 2022 was 34.6% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| CDXS | Sell | CODEXIS INC | $13,477,000 | -51.4% | 1,288,450 | -4.2% | 6.08% | -29.5% |
| CRNX | Sell | CRINETICS PHARMACEUTICALS INC | $12,520,000 | -17.7% | 671,300 | -3.1% | 5.64% | +19.5% |
| CYTK | Sell | CYTOKINETICS INC | $11,885,000 | -20.6% | 302,500 | -25.6% | 5.36% | +15.3% |
| KNSA | Sell | KINIKSA PHARMACEUTICALS LTD | $7,890,000 | -28.6% | 814,250 | -26.8% | 3.56% | +3.6% |
| XOMA | Sell | XOMA CORP DEL | $5,861,000 | -22.7% | 263,050 | -2.9% | 2.64% | +12.2% |
| RETA | Sell | REATA PHARMACEUTICALS INCclass a | $5,584,000 | -58.1% | 183,750 | -54.9% | 2.52% | -39.2% |
| PCVX | Sell | VAXCYTE INC | $4,134,000 | -18.9% | 190,000 | -10.0% | 1.86% | +17.7% |
| STXS | Sell | STEREOTAXIS INC | $3,864,000 | -56.8% | 2,099,971 | -12.3% | 1.74% | -37.2% |
| CMRX | Sell | CHIMERIX INC | $2,974,000 | -89.0% | 1,430,000 | -75.8% | 1.34% | -84.0% |
| FBIO | Sell | FORTRESS BIOTECH INC | $2,727,000 | -46.5% | 3,247,180 | -13.4% | 1.23% | -22.4% |
| CLDX | Sell | CELLDEX THERAPEUTICS INC NEW | $2,426,000 | -63.6% | 90,000 | -54.0% | 1.09% | -47.1% |
| Sell | GINKGO BIOWORKS HOLDINGS INCclass a shares | $1,940,000 | -48.2% | 815,000 | -12.3% | 0.87% | -24.9% | |
| VSTM | Sell | VERASTEM INC | $1,844,000 | -43.7% | 1,590,000 | -31.6% | 0.83% | -18.4% |
| LRMR | Sell | LARIMAR THERAPEUTICS INC | $1,828,000 | -52.2% | 932,814 | -1.2% | 0.82% | -30.6% |
| NLTX | Sell | NEOLEUKIN THERAPEUTICS INC | $628,000 | -57.7% | 610,000 | -22.8% | 0.28% | -38.6% |
| MGNX | Sell | MACROGENICS INC | $614,000 | -81.5% | 208,300 | -44.7% | 0.28% | -73.1% |
| Sell | AVALO THERAPEUTICS INC | $225,000 | -78.7% | 450,000 | -69.1% | 0.10% | -69.1% | |
| STRO | Exit | SUTRO BIOPHARMA INC | $0 | – | -89,980 | -100.0% | -0.23% | – |
| RPTX | Exit | REPARE THERAPEUTICS INC | $0 | – | -55,678 | -100.0% | -0.25% | – |
| NCNA | Exit | NUCANA PLCsponsored adr | $0 | – | -878,700 | -100.0% | -0.27% | – |
| AVEO | Exit | AVEO PHARMACEUTICALS INC | $0 | – | -240,000 | -100.0% | -0.42% | – |
| SYBX | Exit | SYNLOGIC INC | $0 | – | -984,200 | -100.0% | -0.73% | – |
| FULC | Exit | FULCRUM THERAPEUTICS INC | $0 | – | -136,000 | -100.0% | -1.00% | – |
| SMLR | Exit | SEMLER SCIENTIFIC INC | $0 | – | -70,000 | -100.0% | -1.08% | – |
| PTGX | Exit | PROTAGONIST THERAPEUTICS INC | $0 | – | -251,500 | -100.0% | -1.85% | – |
| BCYC | Exit | BICYCLE THERAPEUTICS PLCsponsored ads | $0 | – | -175,000 | -100.0% | -2.38% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-08-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CODEXIS INC | 39 | Q3 2023 | 10.9% |
| CHIMERIX INC | 31 | Q3 2022 | 16.4% |
| XOMA CORP DEL | 27 | Q3 2023 | 3.6% |
| FIBROGEN INC | 26 | Q1 2021 | 6.8% |
| BIOLINERX LTD (Does not reflect a reverse stock split effectuated after June 30, 2019) | 26 | Q1 2020 | 2.4% |
| OCULAR THERAPEUTIX INC | 24 | Q3 2023 | 17.6% |
| AXOGEN INC | 20 | Q4 2019 | 18.7% |
| ETON PHARMACEUTICALS INC | 20 | Q3 2023 | 5.6% |
| AMARIN CORP PLC | 20 | Q4 2020 | 6.6% |
| IMPRIMIS PHARMACEUTICALS INC | 19 | Q1 2020 | 5.9% |
View Opaleye Management Inc.'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| CHIMERIX INCSold out | February 13, 2023 | 0 | 0.0% |
| Larimar Therapeutics, Inc. | January 23, 2023 | 1,560,000 | 3.6% |
| TELA Bio, Inc. | June 10, 2022 | 1,557,500 | 10.7% |
| Gemini Therapeutics, Inc. /DESold out | February 01, 2022 | 0 | 0.0% |
| Adamas Pharmaceuticals IncSold out | January 26, 2022 | 0 | 0.0% |
| AVENUE THERAPEUTICS, INC. | February 12, 2021 | 9 | 11.0% |
| Cardiff Oncology, Inc. | February 12, 2021 | 9 | 11.0% |
| EDAP TMS SA | February 12, 2021 | 9 | 11.0% |
| Fortress Biotech, Inc. | February 12, 2021 | 9 | 11.0% |
| Gemini Therapeutics, Inc. /DE | February 12, 2021 | 9 | 11.0% |
View Opaleye Management Inc.'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-04-25 |
| 4 | 2024-04-24 |
| 4 | 2024-04-19 |
| SC 13G/A | 2024-04-09 |
| SC 13G | 2024-04-08 |
| 4 | 2024-03-28 |
| 4 | 2024-03-22 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View Opaleye Management Inc.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.